Open in app

Sign In

Write

Sign In

BlueYard Capital
BlueYard Capital

3.8K Followers

Home

About

Jun 1

BlueYard is hiring an Associate focusing on Breakthrough Engineering

We live in a time where the boundary between science fiction and reality is rapidly blurring. Scientists have used high-power lasers to reproduce the sun’s power on Earth, satellites launched by reusable rockets have made high-speed internet ubiquitous and affordable, and new computer architectures have accelerated super-human AI capabilities and…

Engineering

3 min read

BlueYard is hiring an Associate focusing on Breakthrough Engineering
BlueYard is hiring an Associate focusing on Breakthrough Engineering
Engineering

3 min read


Apr 6

Sensible Bio

The unprecedented speed and success of mRNA vaccines in tackling the COVID-19 pandemic has underscored the demand for mRNA as a next-generation nucleic acid therapy. Hundreds of ongoing clinical trials are currently testing mRNA across more than 20 disease categories. The current production process, called In Vitro Transcription (IVT), has…

Biology

2 min read

Sensible Bio
Sensible Bio
Biology

2 min read


Feb 6

Shell Protocol

In the wake of several high profile collapses among centralized players in the crypto world, DeFi is naturally receiving renewed attention as an alternative to centralized finance platforms. At BlueYard, we’re long-term believers in the potential of DeFi to deliver a superior coordination mechanism for the world’s financial activities. Despite…

Crypto

2 min read

Shell Protocol
Shell Protocol
Crypto

2 min read


Feb 2

If Web3 is to Work… A BlueYard Conversation in Denver

Web3 hangs in the balance and faces a number of existential problems: from security and usability, regulatory headwinds and damaged public trust, to a lack of real-world use cases. To help facilitate a discussion about what needs to change If Web3 Is To Work (and to gain real & sustainable…

Crypto

2 min read

If Web3 is to Work… A BlueYard Conversation in Denver
If Web3 is to Work… A BlueYard Conversation in Denver
Crypto

2 min read


Feb 1

Corintis

For more than 50 years, the technology industry benefited from the tail winds of Moore’s Law. The density of transistors in a silicon microprocessor doubled roughly every 2 years. Up until 10 years ago, that meant that microprocessors got twice as fast every 2 years. Unfortunately, at a certain point…

2 min read

Corintis
Corintis

2 min read


Jan 26

Creasallis

Over the past five years, antibodies have become the best-selling drugs in the pharmaceutical market (in 2018 eight of the top ten best-selling drugs worldwide were biologics). Targeted monoclonal antibodies (mAbs), therapeutic proteins that bind to specific target sites, have become a cornerstone of treatment guidelines for a wide range…

Biology

2 min read

Creasallis
Creasallis
Biology

2 min read


Jan 25

BlueYard: Join Our Team as a Bio + Health focused Principal

We are at the beginning of a new frontier in biology and medicine unparalleled in human history. Scientific advances like the latest generation of CRISPR, new computational methods, entirely new cell and gene therapies, cell-free synthetic biology and breakthroughs we cannot even imagine today will unlock the applications and treatments…

4 min read

BlueYard: Join Our Team as a Bio + Health focused Principal
BlueYard: Join Our Team as a Bio + Health focused Principal

4 min read


Jan 23

Visolis

Two secular trends are disrupting the chemicals space in western economies: A shift from fossil fuels & petrochemicals in an effort to curb greenhouse gas emissions and reduce dependence on Russia/OPEC Moving production of critical commodities onshore and favoring resilience/reliability of supply over lower cost offshore production One of the…

Synthetic Biology

1 min read

Visolis
Visolis
Synthetic Biology

1 min read


Jan 20

ExpressionEdits

Proteins are a foundational pillar in healthcare and behind every major advancement in biotech and synthetic biology for the last half-century, while biotech’s emergence as a new class of therapeutics was driven by the ability to produce proteins using cells or organisms in a controlled manner. Transgenes, artificial gene constructs…

Biology

2 min read

ExpressionEdits
ExpressionEdits
Biology

2 min read


Jan 16

BlueYard x Nucleate Partnership

We are entering a new frontier in biology and medicine unparalleled in human history, with breakthrough advances in gene editing, computational methods, and cell therapies. At the same time, our overall capability of understanding and manipulating biology is improving exponentially. BlueYard’s strategy around biology is based on the premise that…

Biology

2 min read

BlueYard x Nucleate Partnership
BlueYard x Nucleate Partnership
Biology

2 min read

BlueYard Capital

BlueYard Capital

3.8K Followers

BlueYard backs founders building the interconnected elements that can become the fabric of our future.

Following
  • Antoine Scalia

    Antoine Scalia

  • Positive Food Co.

    Positive Food Co.

  • Franco Zeoli

    Franco Zeoli

  • Elizabeth“Beezer”Clarkson

    Elizabeth“Beezer”Clarkson

  • Andrew Hill

    Andrew Hill

See all (18)

Help

Status

Writers

Blog

Careers

Privacy

Terms

About

Text to speech

Teams